

L Number	Hits	Search Text	DB	Time stamp
1	3223840	pax "2"	USPAT	2003/06/23 16:56
2	28	pax near1 "2"	USPAT	2003/06/23 16:56
3	0	pax adj (pax near1 "2")	USPAT	2003/06/23 16:56
4	12	pax near2 (pax near1 "2")	USPAT	2003/06/23 16:56
5	12	pax near1 (pax near1 "2")	USPAT	2003/06/23 16:56
7	0	"pax near1 2"	USPAT; US-PGPUB; EPO	2003/06/23 16:57
8	36	"pax 2"	USPAT; US-PGPUB; EPO	2003/06/23 16:58
9	41	"pax 2" or (pax near1 (pax near1 "2"))	USPAT; US-PGPUB; EPO	2003/06/23 16:58
10	2	("pax 2" or (pax near1 (pax near1 "2"))) same prostate\$	USPAT; US-PGPUB; EPO	2003/06/23 16:58

expression by measuring mRNA or protein levels is described. A method of treating **prostate** cancer comprising the step of administering to the patient an agent which selectively prevents the function of Pax2 is also described. A genetic construct comprising a nucleic acid encoding a mol. capable of preventing the function of Pax2 expressed in a **prostate** cell is discussed.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 4 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
ACCESSION NUMBER: 2000:83005 BIOSIS  
DOCUMENT NUMBER: PREV200000083005  
TITLE: The expression of **PAX-2** in human  
**prostate** cancer.  
AUTHOR(S): Khoubehi, B. (1); Adshead, J.; Kessler, A.; Ogden, C.  
CORPORATE SOURCE: (1) Department of Urology, Community Genetics at Northwick  
Park Hospital, Imperial College, University of London,  
London UK  
SOURCE: European Urology, (Nov., 1999) Vol. 36, No. 5, pp. 511-512.  
Meeting Info.: 3rd World Congress on Urological Research  
Paris, France September 30-October 3, 1999  
ISSN: 0302-2838.  
DOCUMENT TYPE: Conference  
LANGUAGE: English

=> d hist

(FILE 'HOME' ENTERED AT 16:43:59 ON 23 JUN 2003)

FILE 'MEDLINE, BIOSIS, CAPLUS' ENTERED AT 16:44:10 ON 23 JUN 2003

L1 761 S PAX(1A) (2 OR TWO)  
L2 4 S L1 AND (PROSTAT?)  
L3 4 S L1 AND PROSTATE?  
L4 4 DUP REM L3 (0 DUPLICATES REMOVED)

=> d ibib ab 1-4

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:472912 CAPLUS

DOCUMENT NUMBER: 135:71317

TITLE: Modulation of **PAX-2** for controlled apoptosis or survival of cells for therapeutic applications

INVENTOR(S): Goodyer, Paul; Eccles, Roger Michael; Torban, Elena

PATENT ASSIGNEE(S): McGill University, Can.; University of Otago

SOURCE: PCT Int. Appl., 45 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001046405	A2	20010628	WO 2000-CA1545	20001221
WO 2001046405	A3	20020307		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1240321	A2	20020918	EP 2000-984747	20001221
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 2003092657	A1	20030515	US 2002-175138	20020619
PRIORITY APPLN. INFO.:			US 1999-171443P P	19991222
			US 2000-220161P P	20000724
			WO 2000-CA1545 W	20001221

AB The present invention relates to a method of modulating resistance to apoptosis in a patient. The treatment consists of administering to a patient a therapeutically effective amt. of an enhancing agent which selectively inhibits or stimulates the function of **PAX-2**. The enhancing agent of the present invention allows to increase or to reduce resistance to apoptosis depending of targeted cells. Mutations in the **PAX2** gene cause a rare autosomal dominant renal-coloboma syndrome, characterized by optic nerve colobomas and renal hypoplasia. Elevated level of apoptosis was identified in fetal kidney of individuals carrying a **PAX-2** mutation. Pax2-1Neu mutant mice have optic nerve and kidney abnormalities. A method of diagnosing renal-coloboma syndrome, cystic kidney disease, renal hypoplasia, as well as **prostate**, ovarian, bladder or kidney cancer is provided.

L4 ANSWER 2 OF 4 MEDLINE

ACCESSION NUMBER: 2001291661 MEDLINE

DOCUMENT NUMBER: 21265352 PubMed ID: 11371938

TITLE: Expression of the developmental and oncogenic **PAX2** gene in human **prostate** cancer.

AUTHOR: Khoubehi B; Kessler A M; Adshead J M; Smith G L; Smith R D; Ogden C W

CORPORATE SOURCE: Academic Unit of Medical and Community Genetics, Imperial College of Science Technology and Medicine, Kennedy-Galton Centre, Northwick Park Hospital, London, United Kingdom.

SOURCE: JOURNAL OF UROLOGY, (2001 Jun) 165 (6 Pt 1) 2115-20.

Journal code: 0376374. ISSN: 0022-5347.

PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals  
ENTRY MONTH: 200106  
ENTRY DATE: Entered STN: 20010618  
Last Updated on STN: 20010618  
Entered Medline: 20010614

AB PURPOSE: In the human **prostate** cancer cell lines LNCaP, DU145 and PC3, 27 primary **prostate** cancers, 10 benign prostatic hyperplasia specimens and 5 normal **prostates** we investigated the expression pattern of PAX2, a member of the PAX family of developmental control genes. PAX2 is expressed at high levels in developing undifferentiated cells of the urogenital system and is repressed upon terminal differentiation with no expression in normal adult cells. It is also been shown to be a proto-oncogene in mice and is expressed in human renal cell carcinoma. MATERIALS AND METHODS: PAX2 expression was assessed at the RNA level by reverse transcriptase-polymerase chain reaction and Southern blot analysis using specific sets of nucleotides. The expression pattern of PAX2 was reconfirmed at the protein level by immunofluorescence in the cell lines, and by Western blot analysis in primary human **prostate** cancers and benign prostatic tissue. RESULTS: Using reverse transcription-polymerase chain reaction combined with Southern hybridization PAX2 expression was detected in 52% of primary cancers and all 3 cell lines. PAX2 expression in these samples was confirmed at a protein level using immunoblotting and immunofluorescence. PAX2 messenger RNA was not detected in any benign or normal prostatic samples. Immunoblotting of protein from benign prostatic hyperplasia samples confirmed the lack of expression of PAX2 protein. CONCLUSIONS: The expression of PAX2 in **prostate** cancer compared to nonmalignant **prostates** is statistically significant (Fisher's exact test  $p = 0.0004$ ). These results suggest a possible role for PAX2 in **prostate** cancer. Although previous studies have suggested a role for PAX2 for supporting proliferation in undifferentiated cells, no correlation of PAX2 expression with Gleason score was found in **prostate** cancer.

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:592857 CAPLUS  
DOCUMENT NUMBER: 133:175760  
TITLE: **PAX-2** gene expression in the diagnosis of **prostate** cancer and use of the gene as a target for therapy  
INVENTOR(S): Ogden, Christopher William; Adshead, James; Kessling, Anna Maria; Khoubehi, Bijan  
PATENT ASSIGNEE(S): Imperial College Innovations Limited, UK  
SOURCE: PCT Int. Appl., 96 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000049175	A1	20000824	WO 2000-GB586	20000221
W: JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 2002142320	A1	20021003	US 2001-933548	20010820
PRIORITY APPLN. INFO.:			GB 1999-3841	A 19990220
			WO 2000-GB586	A1 20000221

AB A method of diagnosing **prostate** cancer by detection of Pax2 gene